Cargando…
COVID-19 and Vaccine-Induced Thrombosis
Coronavirus disease 2019 (COVID-19), a highly contagious infectious disease, has had a catastrophic effect on the world’s demographics resulting in more than 2.9 million deaths worldwide till January 2021. It can lead to systemic multi-organ complications; in particular, venous and arterial thromboe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Research Institute of Tuberculosis and Lung Disease
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423859/ https://www.ncbi.nlm.nih.gov/pubmed/37583774 |
_version_ | 1785089542499336192 |
---|---|
author | Sharif-Kashani, Babak Shafaghi, Shadi Naghashzadeh, Farah Mohamadnia, Abdolreza Rahdar, Mohammad Hajimoradi, Maryam Noorali, Sima |
author_facet | Sharif-Kashani, Babak Shafaghi, Shadi Naghashzadeh, Farah Mohamadnia, Abdolreza Rahdar, Mohammad Hajimoradi, Maryam Noorali, Sima |
author_sort | Sharif-Kashani, Babak |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), a highly contagious infectious disease, has had a catastrophic effect on the world’s demographics resulting in more than 2.9 million deaths worldwide till January 2021. It can lead to systemic multi-organ complications; in particular, venous and arterial thromboembolism risk is significantly increased. Venous thromboembolism (VTE) occurs in 22.7% of patients with COVID-19 in the ICU and 8% in non-ICU hospitalized patients. Studies evaluating thromboprophylaxis strategies in patients with COVID-19 are needed to improve the prevention of VTE. VTE is the most commonly reported thrombotic complication, with higher incidence rates among critically ill patients. Several vaccines have been licensed and are currently used to combat the COVID-19 pandemic. Also, several cases of vaccine-induced thrombosis have been reported. Vaccination remains the most critical measure to curb the COVID-19 pandemic. There is a broad consensus that the benefits of vaccination greatly outweigh the potential risks of rare vaccine side effects, such as vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, the importance of vaccination should be emphasized. This statement aims to focus on VITT. |
format | Online Article Text |
id | pubmed-10423859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | National Research Institute of Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-104238592023-08-15 COVID-19 and Vaccine-Induced Thrombosis Sharif-Kashani, Babak Shafaghi, Shadi Naghashzadeh, Farah Mohamadnia, Abdolreza Rahdar, Mohammad Hajimoradi, Maryam Noorali, Sima Tanaffos Review Article Coronavirus disease 2019 (COVID-19), a highly contagious infectious disease, has had a catastrophic effect on the world’s demographics resulting in more than 2.9 million deaths worldwide till January 2021. It can lead to systemic multi-organ complications; in particular, venous and arterial thromboembolism risk is significantly increased. Venous thromboembolism (VTE) occurs in 22.7% of patients with COVID-19 in the ICU and 8% in non-ICU hospitalized patients. Studies evaluating thromboprophylaxis strategies in patients with COVID-19 are needed to improve the prevention of VTE. VTE is the most commonly reported thrombotic complication, with higher incidence rates among critically ill patients. Several vaccines have been licensed and are currently used to combat the COVID-19 pandemic. Also, several cases of vaccine-induced thrombosis have been reported. Vaccination remains the most critical measure to curb the COVID-19 pandemic. There is a broad consensus that the benefits of vaccination greatly outweigh the potential risks of rare vaccine side effects, such as vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, the importance of vaccination should be emphasized. This statement aims to focus on VITT. National Research Institute of Tuberculosis and Lung Disease 2022-04 /pmc/articles/PMC10423859/ /pubmed/37583774 Text en Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Review Article Sharif-Kashani, Babak Shafaghi, Shadi Naghashzadeh, Farah Mohamadnia, Abdolreza Rahdar, Mohammad Hajimoradi, Maryam Noorali, Sima COVID-19 and Vaccine-Induced Thrombosis |
title | COVID-19 and Vaccine-Induced Thrombosis |
title_full | COVID-19 and Vaccine-Induced Thrombosis |
title_fullStr | COVID-19 and Vaccine-Induced Thrombosis |
title_full_unstemmed | COVID-19 and Vaccine-Induced Thrombosis |
title_short | COVID-19 and Vaccine-Induced Thrombosis |
title_sort | covid-19 and vaccine-induced thrombosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423859/ https://www.ncbi.nlm.nih.gov/pubmed/37583774 |
work_keys_str_mv | AT sharifkashanibabak covid19andvaccineinducedthrombosis AT shafaghishadi covid19andvaccineinducedthrombosis AT naghashzadehfarah covid19andvaccineinducedthrombosis AT mohamadniaabdolreza covid19andvaccineinducedthrombosis AT rahdarmohammad covid19andvaccineinducedthrombosis AT hajimoradimaryam covid19andvaccineinducedthrombosis AT nooralisima covid19andvaccineinducedthrombosis |